TABLE 1.
Study, year (ref) | AD model | Supplement | Duration | Dose | Outcome |
Teng et al., 2015 (108) | Transgenic APP/PS1 rats | DHA from algal sources | 4 mo | 0.6% (wt:wt) of the diet | Reduced Aβ plaque density |
Improved behavioral testing | |||||
Hosono et al., 2015 (109) | Tg2576 mice | DHA | 4 mo | 2.4 g/kg diet | Reduced Aβ(1–42)-to-Aβ(1–40) ratio |
Torres et al., 2014 (110) | Transgenic 5xFAD mice | 2-Hydroxy DHA | 4 mo | 15 mg ⋅ kg–1 ⋅ d−1 | Reduction in Aβ accumulation |
Improved cognitive scores | |||||
Ma et al., 2014 (111) | Tau knockout mice | DHA alone or with α-lipoic acid | 5 mo | 0.6% DHA (or with 500 ppm α-lipoate) | Protected against hyperphosphorylation |
Lower hippocampal synaptic deficits | |||||
Improved Morris water maze deficits | |||||
Fiol-deRoque et al., 2013 (112) | Transgenic 5xFAD mice | 2-Hydroxy DHA | 4 mo | 15 mg ⋅ kg–1 ⋅ d−1 | Improved radial arm maze test scores |
Labrousse et al., 2012 (113) | Aged C57Bl6/J mice | EPA+DHA | 2 mo | 5.45 g EPA + 3.6 g DHA/kg diet | Reduced inflammatory markers |
Improved spatial memory deficits | |||||
Kariv-Inbal et al., 2012 (114) | ApoE-targeted replacement mice | Fish oil | 4 mo | 3.03 g fish oil/kg diet | Reduced hippocampal Aβ concentrations |
Improved behavioral performance | |||||
Hashimoto et al., 2011 (115) | Aβ-infused rats | Purified EPA+DHA | 12 wk | 300 mg ⋅ kg–1 ⋅ d−1 | Improved reference and working memory |
Aβ, amyloid β APP, amyloid precursor protein; ppm, parts per million; PS1, presenilin 1; ref, reference.